Baxalta Inc, a drugmaker, is in talks to acquire Ariad Pharmaceuticals Inc in hopes of boosting its oncology business. Ariad is a developer of leukemia and lung cancer treatments, but there is no certainty a deal will be reached. Shares for the firm rose 43% to $10 in afternoon trading. Shares for Baxalta dropped 4% to $34.86. Baxalta is currently being courted by drugmaker Shire PLC who has made a $30 billion bid for the company.